Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2015-10-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
第二届监事会第二十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 25th meeting of the second Supervisory Board of Shandong Ruikang Pharmaceutical Co., Ltd. The key content is the approval of the company's 2015 third quarter report, confirming that the report complies with relevant laws and regulations and accurately reflects the company's operating status for that period. The document is short (718 characters) and primarily serves as a meeting resolution announcement rather than the report itself. It does not contain the actual financial data or detailed analysis of the quarterly report but certifies its approval. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal disclosure related to compliance and governance but not the full interim/quarterly report itself.
2015-10-25 Chinese
2015年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of Shandong Ruikang Pharmaceutical Co., Ltd. It contains detailed financial data including balance sheet items, profit and loss items, cash flow statements, shareholder information, and management's discussion of financial performance and outlook for the quarter ending in 2015. The length of the document (8763 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2015
2015-10-25 Chinese
股价异动公告
Regulatory Filings Classification · 95% confidence The document is a stock price abnormal fluctuation announcement by Shandong Ruikang Pharmaceutical Co., Ltd. It discusses the unusual stock price movement, verification of relevant information, and risk warnings. It references a board meeting approving a non-public issuance plan but does not contain financial statements or detailed financial data. The document is short (1150 characters) and serves as a regulatory disclosure about stock price movements and related company information. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement related to stock price abnormality and information disclosure compliance, which fits best under Regulatory Filings (RNS).
2015-10-12 Chinese
第二届董事会第三十次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 30th meeting of the second board of directors of Shandong Ruikang Pharmaceutical Co., Ltd. It includes voting results on various proposals related to a non-public issuance of A shares, including the issuance plan, pricing, use of proceeds, related party transactions, and authorization for the board to handle related matters. The document is dated October 9, 2015, and references compliance with Chinese securities laws and regulations. It is not a full financial report, audit report, or earnings release, but rather a formal announcement of board meeting decisions, including approvals and authorizations. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length (7024 characters) and content confirm it is not a brief notice or a report publication announcement but a substantive board resolution announcement.
2015-10-08 Chinese
独立董事关于第二届董事会第三十次会议审议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters reviewed at the 30th meeting of the second board of directors of Shandong Ruikang Pharmaceutical Co., Ltd. It discusses the non-public issuance of A shares, related pricing, compliance with laws and regulations, associated transactions, and the procedures for board and shareholder approvals. The document is focused on governance and board-level review of financing and related party transactions, rather than being a full financial report or earnings release. It is not a simple announcement but a detailed opinion on board matters related to capital raising and associated governance issues. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board related to company management and governance.
2015-10-08 Chinese
复牌提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of trading (复牌提示性公告) of the company's stock after a period of suspension due to a planned non-public stock issuance. It references multiple prior announcements about the suspension and progress updates, and states that the stock will resume trading on a specific date. There is no detailed financial data, no full report, and the document mainly serves as a notice about the stock resumption and related procedural updates. The document length is only 1847 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about trading status and corporate actions but not a full financial or capital report.
2015-10-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.